A Bagnato

Summary

Affiliation: Regina Elena Cancer Institute
Country: Italy

Publications

  1. ncbi Endothelin-1 stimulates cyclooxygenase-2 expression in ovarian cancer cells through multiple signaling pathways: evidence for involvement of transactivation of the epidermal growth factor receptor
    Francesca Spinella
    Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Rome, Italy
    J Cardiovasc Pharmacol 44:S140-3. 2004
  2. ncbi The endothelin axis as therapeutic target in human malignancies: present and future
    Anna Bagnato
    Molecular Pathology Laboratory, Regina Elena National Cancer Institute, Via delle Messi d Oro 156, 00158 Rome, Italy
    Curr Pharm Des 18:2720-33. 2012
  3. ncbi Endothelin receptor blockade inhibits proliferation of Kaposi's sarcoma cells
    A Bagnato
    Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Via delle Messi d Oro 156, 00158 Rome, Italy
    Am J Pathol 158:841-7. 2001
  4. ncbi Emerging role of endothelin-1 in tumor angiogenesis
    Anna Bagnato
    Molecular Pathology Laboratory, Regina Elena Cancer Institute, Via delle Messi d Oro 156, 00158 Rome, Italy
    Trends Endocrinol Metab 14:44-50. 2003
  5. ncbi Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression
    Anna Bagnato
    Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Via delle Messi d Oro 156, 00158 Rome, Italy
    Cancer Res 64:1436-43. 2004
  6. ncbi Emerging role of the endothelin axis in ovarian tumor progression
    Anna Bagnato
    Molecular Pathology and Ultrastructure Laboratory, Regina Elena Cancer Institute, Rome, Italy
    Endocr Relat Cancer 12:761-72. 2005
  7. ncbi The endothelin axis in cancer
    Anna Bagnato
    Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Via delle Messi d Oro 156, 00158 Rome, Italy
    Int J Biochem Cell Biol 40:1443-51. 2008
  8. ncbi The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy
    Anna Bagnato
    Molecular Pathology and Ultrastructure Laboratory, Regina Elena Cancer Institute, Via delle Messi d Oro 156, Rome, Italy
    Can J Physiol Pharmacol 86:473-84. 2008
  9. ncbi Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis
    Anna Bagnato
    Molecular Pathology and Ultrastructure Laboratory, Regina Elena Cancer Institute, Rome, Italy
    Cells Tissues Organs 185:85-94. 2007
  10. ncbi Role of endothelin-1 in neovascularization of ovarian carcinoma
    D Salani
    Laboratories of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Rome, Italy
    Am J Pathol 157:1537-47. 2000

Collaborators

  • J B Nelson
  • Adriana Albini
  • A Venuti
  • Annamaria Biroccio
  • Giampaolo Tortora
  • Bruno Battistini
  • Francesca Spinella
  • Laura Rosanò
  • Valeriana Di Castro
  • Pier Giorgio Natali
  • Maria Rita Nicotra
  • Samantha Decandia
  • Debora Salani
  • Donatella Del Bufalo
  • D Salani
  • Shoukat Dedhar
  • Giacomo Elia
  • Alessia Cirilli
  • L Rosano
  • P G Natali
  • V Di Castro
  • Martina Del Duca
  • Arnaldo Caruso
  • Erica Salvati
  • Emirena Garrafa
  • Stefano Masi
  • Roberta Cianfrocca
  • Antonio Garcia De Herreros
  • Antonio Muller
  • Giulia Genovesi
  • Paola Simeone
  • Robert J Padley
  • Marco Varmi
  • Daniela Trisciuoglio
  • M Varmi
  • F Spinella
  • R Tecce
  • M R Nicotra

Detail Information

Publications46

  1. ncbi Endothelin-1 stimulates cyclooxygenase-2 expression in ovarian cancer cells through multiple signaling pathways: evidence for involvement of transactivation of the epidermal growth factor receptor
    Francesca Spinella
    Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Rome, Italy
    J Cardiovasc Pharmacol 44:S140-3. 2004
    ..These results suggest that the pharmacological blocking of endothelin-A receptor is an attractive strategy to control the cyclooxygenase-2 protein expression in ovarian carcinoma...
  2. ncbi The endothelin axis as therapeutic target in human malignancies: present and future
    Anna Bagnato
    Molecular Pathology Laboratory, Regina Elena National Cancer Institute, Via delle Messi d Oro 156, 00158 Rome, Italy
    Curr Pharm Des 18:2720-33. 2012
    ....
  3. ncbi Endothelin receptor blockade inhibits proliferation of Kaposi's sarcoma cells
    A Bagnato
    Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Via delle Messi d Oro 156, 00158 Rome, Italy
    Am J Pathol 158:841-7. 2001
    ..Such findings demonstrate that ET-1 participates on KS pathogenesis acting as an autocrine growth factor and that ET-1 receptor antagonists may thus be novel candidates for therapeutic intervention...
  4. ncbi Emerging role of endothelin-1 in tumor angiogenesis
    Anna Bagnato
    Molecular Pathology Laboratory, Regina Elena Cancer Institute, Via delle Messi d Oro 156, 00158 Rome, Italy
    Trends Endocrinol Metab 14:44-50. 2003
    ....
  5. ncbi Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression
    Anna Bagnato
    Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Via delle Messi d Oro 156, 00158 Rome, Italy
    Cancer Res 64:1436-43. 2004
    ..Pharmacological interruption of ET(B)R signaling may represent a novel therapeutic strategy in the treatment of this malignancy...
  6. ncbi Emerging role of the endothelin axis in ovarian tumor progression
    Anna Bagnato
    Molecular Pathology and Ultrastructure Laboratory, Regina Elena Cancer Institute, Rome, Italy
    Endocr Relat Cancer 12:761-72. 2005
    ....
  7. ncbi The endothelin axis in cancer
    Anna Bagnato
    Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Via delle Messi d Oro 156, 00158 Rome, Italy
    Int J Biochem Cell Biol 40:1443-51. 2008
    ....
  8. ncbi The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy
    Anna Bagnato
    Molecular Pathology and Ultrastructure Laboratory, Regina Elena Cancer Institute, Via delle Messi d Oro 156, Rome, Italy
    Can J Physiol Pharmacol 86:473-84. 2008
    ....
  9. ncbi Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis
    Anna Bagnato
    Molecular Pathology and Ultrastructure Laboratory, Regina Elena Cancer Institute, Rome, Italy
    Cells Tissues Organs 185:85-94. 2007
    ....
  10. ncbi Role of endothelin-1 in neovascularization of ovarian carcinoma
    D Salani
    Laboratories of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Rome, Italy
    Am J Pathol 157:1537-47. 2000
    ..These findings indicate that ET-1 could modulate tumor angiogenesis, acting directly and in part through VEGF...
  11. ncbi Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth
    A Bagnato
    Laboratory of Molecular Pathology, Regina Elena Cancer Institute, Rome, Italy
    Cancer Res 59:720-7. 1999
    ..In conclusion, the present data demonstrate a novel mechanism in the growth control of ovarian carcinoma in vivo mediated by the ET-1 autocrine loop that selectively occurs via the ET(A)R...
  12. ncbi Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma
    Laura Rosanò
    Laboratories of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, 00158 Rome, Italy
    Cancer Res 63:2447-53. 2003
    ..Interruption of ET(A)R signaling therefore, represents, a promising therapeutic strategy in ovarian carcinoma...
  13. ncbi Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy
    A Venuti
    Laboratories of Virology, Regina Elena Cancer Institue, 00158 Rome, Italy
    FASEB J 14:2277-83. 2000
    ..These results demonstrate that ET-1 participates in the progression of neoplastic growth in HPV-associated carcinoma, in which ETAR are increased and could be targeted for antitumor therapy...
  14. ncbi The E5 oncoprotein of human papillomavirus type 16 enhances endothelin-1-induced keratinocyte growth
    A Venuti
    Laboratory of Virology, Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Institute for Cancer Research, CRS, Via delle Messi d Oro 156, Rome, 00158, Italy
    Virology 248:1-5. 1998
    ..In conclusion, our data demonstrate that E5 enhances ligand signaling in keratinocytes outside the EGF pathway by the amplification of the proliferative effect of ET-1/ETA receptor signaling...
  15. ncbi Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells
    L Rosano
    Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Via delle Messi d Oro 156, 00158 Rome, Italy
    Cancer Res 61:8340-6. 2001
    ..Therefore, ET-1 may represent a key component of more aggressive ligand-induced invasiveness of ovarian carcinoma...
  16. ncbi Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells
    Laura Rosanò
    Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Rome, Italy
    Cancer Res 65:11649-57. 2005
    ..Collectively, these findings provide evidence of a critical role for the ET-1/ET(A)R axis during distinct steps of ovarian carcinoma progression and identify novel targets of therapeutic intervention...
  17. ncbi The autonomous growth of human papillomavirus type 16-immortalized keratinocytes is related to the endothelin-1 autocrine loop
    A Venuti
    Laboratory of Virology, Regina Elena Institute for Cancer Research, Rome, Italy
    J Virol 71:6898-904. 1997
    ..These data suggest a new mechanism in the growth control of HPV-transformed cells mediated by the upregulation of ET-1 autocrine loop...
  18. ncbi Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo
    Laura Rosanò
    Laboratories of Molecular Pathology and Ultrastructure and Immunology, Regina Elena Cancer Institute, and the Molecular Biology and Pathology Institute, Consiglio Nazionale delle Ricerche, Rome, Italy
    Am J Pathol 163:753-62. 2003
    ..Such activities can be blocked by the ET(A/B)R antagonists, which may be effective anti-angiogenic and anti-tumor molecules for the treatment of Kaposi's sarcoma...
  19. ncbi Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade
    Anna Bagnato
    Laboratoryies of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Rome, Italy
    Cancer Res 62:6381-4. 2002
    ..These results demonstrate that by inhibiting cell proliferation and angiogenesis, this small molecule may help to control cervical cancer by either monotherapy or combination therapy...
  20. ncbi ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo
    Laura Rosanò
    Molecular Pathology Laboratory, Regina Elena Cancer Institute, Via delle Messi d Oro 156, 00158 Rome, Italy
    Mol Cancer Ther 6:2003-11. 2007
    ....
  21. ncbi Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity
    Laura Rosanò
    Molecular Pathology Laboratory, Regina Elena Cancer Institute, Rome, Italy
    Cancer Res 67:6351-9. 2007
    ..The cross-signaling between the EGFR/ET(A)R pathways provides a rationale to combine EGFR inhibitors with ET(A)R antagonists, identifying new effective therapeutic opportunities for ovarian cancer...
  22. ncbi Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells
    Francesca Spinella
    Laboratory of Molecular Pathology and Ultrastructure, Rome Oncogenomic Center, and Laboratory of Immunology, Regina Elena Cancer Institute, Via delle Messi d Oro 156, 00158 Rome, Italy
    Cancer Res 67:1725-34. 2007
    ..New therapeutic strategies using specific ET(B)R antagonist could provide an improved approach to the treatment of melanoma by inhibiting tumor growth and progression...
  23. ncbi Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma
    Francesca Spinella
    Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Via delle Messi d'Oro, 156, 00158 Rome, Italy
    Mol Cancer Ther 5:1483-92. 2006
    ....
  24. ncbi Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression
    Laura Rosanò
    Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Via delle Messi d Oro 156, 00158 Rome, Italy
    Exp Biol Med (Maywood) 231:1128-31. 2006
    ..Collectively, these findings provide evidence of a critical role for the ET-1/ET(A)R axis during distinct steps of ovarian carcinoma progression, thus underlining this axis as a potential target in the treatment of ovarian cancer...
  25. ncbi Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan
    Laura Rosanò
    Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Rome, Italy
    J Cardiovasc Pharmacol 44:S132-5. 2004
    ..The antitumor, anti-angiogenic, and apoptotic activities obtained with atrasentan and the enhanced efficacy of cytotoxic agents provide a rationale for its clinical evaluation in ovarian carcinoma...
  26. ncbi Endothelin-1 acts as a survival factor in ovarian carcinoma cells
    Donatella Del Bufalo
    Experimental Chemotherapy Laboratory, Regina Elena Cancer Institute, Via delle Messi d'Oro 156, 00158 Rome, Italy
    Clin Sci (Lond) 103:302S-305S. 2002
    ....
  27. ncbi Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells
    Francesca Spinella
    Laboratory of Molecular Pathology, Regina Elena Cancer Institute, 00158 Rome, Italy
    J Biol Chem 277:27850-5. 2002
    ..Our results suggest that new therapeutic strategies using specific ET(A)R antagonists could provide an additional approach to the treatment of ovarian carcinoma by inhibiting neovascularization as well as tumor cell growth...
  28. ncbi Endothelin-B receptor blockade inhibits molecular effectors of melanoma cell progression
    Laura Rosanò
    Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Rome, Italy
    J Cardiovasc Pharmacol 44:S136-9. 2004
    ....
  29. ncbi Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells
    Francesca Spinella
    Laboratories of Molecular Pathology and Ultrastructure and Immunology, Regina Elena Cancer Institute, Rome, Italy
    Clin Cancer Res 10:4670-9. 2004
    ..Pharmacological blockade of the ET(A)R is an attractive strategy to control COX-2 induction, which has been associated with ovarian carcinoma progression and chemoresistance...
  30. ncbi Targeting endothelin receptor type A in human cervical carcinoma cells
    Alessia Cirilli
    Laboratory of Virology, Regina Elena Cancer Institute, Rome, Italy
    J Cardiovasc Pharmacol 44:S72-5. 2004
    ..In conclusion, targeting the endothelin-A receptor, but not the endothelin-B receptor, may be a valid tool in the therapy of cervical carcinoma...
  31. ncbi ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro
    Debora Salani
    Laboratory of Molecular Pathology, Regina Elena Cancer Institute, Via delle Messi d'Oro 156, 00158 Rome, Italy
    Clin Sci (Lond) 103:318S-321S. 2002
    ....
  32. ncbi Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells
    Francesca Spinella
    Laboratory of Molecular Pathology, Regina Elena National Cancer Institute, Rome, Italy
    PLoS ONE 5:e11241. 2010
    ....
  33. ncbi Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion
    Francesca Spinella
    Laboratories of Molecular Pathology and Ultrastructure and Immunology, Regina Elena Cancer Institute, 00158 Rome, Italy
    J Biol Chem 279:46700-5. 2004
    ..Pharmacological blockade of ETAR can therefore represent an additional strategy to control PGE2 signaling, which has been associated with ovarian carcinoma progression...
  34. ncbi ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation
    Laura Rosanò
    Molecular Pathology Laboratory, Regina Elena Cancer Institute, Via delle Messi d Oro 156, 00158 Rome, Italy
    Exp Biol Med (Maywood) 231:1132-5. 2006
    ..In conclusion, our data demonstrate that ZD4054 is capable in inhibiting the proliferative activity of ET-1, indicating that this specific ET(A)R antagonist may be a potential candidate in developing novel treatment of ovarian carcinoma...
  35. ncbi Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma
    Laura Rosanò
    Laboratory of Molecular Pathology and Ultrastructure, Regina Elena Cancer Institute, Via delle Messi d Oro 156, 00158 Rome, Italy
    Mol Cancer Ther 5:833-42. 2006
    ..These data show that ILK functions as a downstream mediator of the ET-1/ET(A)R axis to potentiate aggressive cellular behavior. Thus, the ILK-related signaling cascade can be efficiently targeted by pharmacologic blockade of ET(A)R...
  36. ncbi Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells
    Francesca Spinella
    Laboratories of Molecular Pathology and Ultrastructure and Immunology, Regina Elena Cancer Institute, Rome 00158, Italy
    J Biol Chem 278:41294-301. 2003
    ....
  37. ncbi Endothelin-1 promotes proteolytic activity of ovarian carcinoma
    Laura Rosanò
    Laboratory of Molecular Pathology, Regina Elena Cancer Institute, Via delle Messi d Oro 156, 00158 Rome, Italy
    Clin Sci (Lond) 103:306S-309S. 2002
    ....
  38. ncbi The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer
    Laura Rosanò
    Molecular Pathology Laboratory, Regina Elena National Cancer Institute, Via delle Messi d Oro 156, 00158 Rome, Italy
    Am J Physiol Regul Integr Comp Physiol 299:R395-404. 2010
    ....
  39. ncbi Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation
    Donatella Del Bufalo
    Experimental Chemotherapy Laboratories, Regina Elena Cancer Institute, Rome, Italy
    Mol Pharmacol 61:524-32. 2002
    ....
  40. ncbi Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis
    Laura Rosanò
    Laboratories of Molecular Pathology, Experimental Chemotherapy, and Immunology, Regina Elena Cancer Institute, 00158 Rome, Italy
    Proc Natl Acad Sci U S A 106:2806-11. 2009
    ..ZD4054 treatment significantly inhibits metastases, suggesting that specific ET(A)R antagonists, by disabling multiple signaling activated by ET(A)R/beta-arrestin, may represent new therapeutic opportunities for ovarian cancer...
  41. ncbi Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target
    Francesca Spinella
    Molecular Pathology and UltrastructureLaboratory, Regina Elena Cancer Institute, Via delle Messi d'Oro 156, 00158 Rome, Italy
    Exp Biol Med (Maywood) 231:1123-7. 2006
    ....
  42. ncbi Endothelin receptor blockade inhibits the growth of human papillomavirus-associated cervical carcinoma
    Aldo Venuti
    Laboratory of Virology, Regina Elena Cancer Institute, Via delle Messi d Oro 156, 00158 Rome, Italy
    Clin Sci (Lond) 103:310S-313S. 2002
    ..In conclusion, an ET-1 autocrine loop is involved in tumour cell proliferation via ET(A)R, and ABT-627 is effective in controlling proliferation of cervical carcinoma cells...
  43. ncbi Targeting endothelin axis in cancer
    Anna Bagnato
    Molecular Pathology and Ultrastructure Laboratory, Regina Elena Cancer Institute, Rome, Italy
    Cancer Treat Res 119:293-314. 2004
  44. ncbi Role of the endothelin axis and its antagonists in the treatment of cancer
    A Bagnato
    Molecular Pathology Laboratory A, Regina Elena National Cancer Institute, Rome, Italy
    Br J Pharmacol 163:220-33. 2011
    ..Given the unexpected opportunities to affect pleiotrophic tumorigenic signals by targeting ET(A)-mediated pathways in a number of cancers, the evaluation of ET-targeted therapy in cancer warrants further investigation...
  45. ncbi Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade
    Francesca Spinella
    Molecular Pathology and Immunology Laboratories, Regina Elena Cancer Institute and Molecular Biology and Pathology Institute, National Research Council, Rome, Italy
    Cancer Res 69:2669-76. 2009
    ..Our results suggest that ET-1 axis is indeed a new player in lymphangiogenesis and that targeting pharmacologically ET(B)R and related signaling cascade may be therapeutically exploited in a variety of diseases including cancer...
  46. ncbi The endothelin axis: emerging role in cancer
    Joel Nelson
    University of Pittsburgh School of Medicine, 5200 Centre Avenue, Pittsburgh, PA 15232, USA
    Nat Rev Cancer 3:110-6. 2003
    ..The place of ET-receptor antagonists in cancer therapy for a range of malignancies merits further investigation...